​

Funding Round

Series B - Attovia Therapeutics

Series B - Attovia Therapeutics

Investment Firm

Overview

Attovia Therapeutics develops a pipeline of biotherapeutics for immune-mediated diseases.

Announced Date

May 09, 2024

Closed on Date

May 09, 2024

Funding Type

Series B

Highlights

Location

United States, North America

Social

Investor Lead

Goldman Sachs Asset Management

Goldman Sachs Asset Management

Goldman Sachs Asset Management is a debt and early_stage_venture and late_stage_venture and private_equity firm.

Participant Investors

10

Investor Name
Participant InvestorGoldman Sachs Asset Management
Participant InvestorRedmile Group
Participant InvestorEcoR1 Capital
Participant InvestorvenBio Partners
Participant InvestorIllumina Ventures

Round Details and Background

Attovia Therapeutics raised $105000000 on 2024-05-09 in Series B

Attovia Therapeutics develops a pipeline of biotherapeutics for immune-mediated diseases.

Company Funding History

2

Announcment DateTransaction NameNumber Of InvestorsLead InvestorMoney Raised
Jun 20, 2023
Series A - Attovia Therapeutics
3-60.0M
May 09, 2024
Series B - Attovia Therapeutics
10-105.0M

Recent Activity

There is no recent news or activity for this profile.